Prespecified falsification end points: can they validate true observational associations?
JAMA
.
2013 Jan 16;309(3):241-2.
doi: 10.1001/jama.2012.96867.
Authors
Vinay Prasad
1
,
Anupam B Jena
Affiliation
1
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
PMID:
23321761
DOI:
10.1001/jama.2012.96867
No abstract available
MeSH terms
Causality*
Drug-Related Side Effects and Adverse Reactions*
Endpoint Determination*
Fraud*
Observation*
Observer Variation
Product Surveillance, Postmarketing
Research Design
Sample Size